文献速递精神分裂症与精神病性障碍

精神分裂症多基因易感性与症状维度及认知能力的关联

Associations Between Schizophrenia Polygenic Liability, Symptom Dimensions, and Cognitive Ability in Schizophrenia.
PubMed 文献 · JAMA Psychiatry · 2021-01-01

该遗传关联研究纳入1220例精神分裂症患者,用验证性因子分析构建症状与认知维度,并分析多基因风险评分(PRS)与这些维度的关联。结果显示精神分裂症PRS与紊乱症状维度得分升高相关,当前认知能力则与精神分裂症和智力两种遗传易感性相关。

要点

  • 精神分裂症PRS与紊乱症状维度得分升高相关,与其他症状维度无关。
  • 当前认知能力与精神分裂症PRS负相关,与智力PRS正相关。
  • 控制病前IQ后,当前认知仍与精神分裂症PRS负相关,与智力PRS无关。

核心结论

  • 精神分裂症遗传易感性与更高的紊乱症状维度得分相关,但与其他症状维度无关。
  • 精神分裂症患者的认知表现反映智力和精神分裂症两种遗传易感性的独立贡献。

研究设计与样本

  • 遗传关联研究,采用来自英国社区、住院和志愿部门精神卫生服务的3个横断面样本,共1220例精神分裂症患者。
  • 使用验证性因子分析从SAPS、SANS和MATRICS共识认知成套测验的终生评定中构建表型维度,并分析多基因风险评分与这些维度的关联。

主要发现

  • 在5因子模型中,精神分裂症PRS与紊乱症状维度得分升高相关(β=0.14;95%CI,0.07-0.22;P=2.80×10-4)。
  • 在3因子模型中,精神分裂症PRS与紊乱症状维度得分升高相关(β=0.10;95%CI,0.05-0.15;P=2.80×10-4)。
  • 当前认知能力与精神分裂症遗传易感性相关(β=-0.11;95%CI,-0.19至-0.04;P=1.63×10-3),与智力遗传易感性相关(β=0.23;95%CI,0.16-0.30;P=1.52×10-10)。
  • 控制估计的病前IQ后,当前认知表现与精神分裂症PRS相关(β=-0.08;95%CI,-0.14至-0.02;P=8.50×10-3),但与智力PRS无关。

临床怎么用

  • 对精神分裂症患者评估紊乱症状维度时,可考虑遗传易感性背景对症状异质性的潜在影响。
  • 认知评估结果解读时需注意精神分裂症与智力遗传易感性的独立贡献,不宜仅归因于单一遗传因素。

局限性

  • 原文未报告局限性相关内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Schizophrenia is a clinically heterogeneous disorder. It is currently unclear how variability in symptom dimensions and cognitive ability is associated with genetic liability for schizophrenia. OBJECTIVE: To determine whether phenotypic dimensions within schizophrenia are associated with genetic liability to schizophrenia, other neuropsychiatric disorders, and intelligence. DESIGN, SETTING, AND PARTICIPANTS: In a genetic association study, 3 cross-sectional samples of 1220 individuals with a diagnosis of schizophrenia were recruited from community, inpatient, and voluntary sector mental health services across the UK. Confirmatory factor analysis was used to create phenotypic dimensions from lifetime ratings of the Scale for the Assessment of Positive Symptoms, Scale for the Assessment of Negative Symptoms, and the MATRICS Consensus Cognitive Battery. Analyses of polygenic risk scores (PRSs) were used to assess whether genetic liability to schizophrenia, other neuropsychiatric disorders, and intelligence were associated with these phenotypic dimensions. Data collection for the cross-sectional studies occurred between 1993 and 2016. Data analysis for this study occurred between January 2019 and March 2021. MAIN OUTCOMES AND MEASURES: Outcome measures included phenotypic dimensions defined from confirmatory factor analysis relating to positive symptoms, negative symptoms of diminished expressivity, negative symptoms of motivation and pleasure, disorganized symptoms, and current cognitive ability. Exposure measures included PRSs for schizophrenia, bipolar disorder, major depression, attention-deficit/hyperactivity disorder, autism spectrum disorder, and intelligence. RESULTS: Of the 1220 study participants, 817 were men (67.0%). Participants' mean (SD) age at interview was 43.10 (12.74) years. Schizophrenia PRS was associated with increased disorganized symptom dimension scores in both a 5-factor model (β = 0.14; 95% CI, 0.07-0.22; P = 2.80 × 10-4) and a 3-factor model across all samples (β = 0.10; 95% CI, 0.05-0.15; P = 2.80 × 10-4). Current cognitive ability was associated with genetic liability to schizophrenia (β = -0.11; 95% CI, -0.19 to -0.04; P = 1.63 × 10-3) and intelligence (β = 0.23; 95% CI, 0.16-0.30; P = 1.52 × 10-10). After controlling for estimated premorbid IQ, current cognitive performance was associated with schizophrenia PRS (β = -0.08; 95% CI, -0.14 to -0.02; P = 8.50 × 10-3) but not intelligence PRS. CONCLUSIONS AND RELEVANCE: The findings of this study suggest that genetic liability for schizophrenia is associated with higher disorganized dimension scores but not other symptom dimensions. Cognitive performance in schizophrenia appears to reflect distinct contributions from genetic liabilities to both intelligence and schizophrenia.

来源:JAMA Psychiatry,查看原文。版权归原作者所有。

引用

  1. Legge SE, Cardno AG, Allardyce J, et al. Associations Between Schizophrenia Polygenic Liability, Symptom Dimensions, and Cognitive Ability in Schizophrenia. JAMA Psychiatry. 2021. PMID: 34347035. doi:10.1001/jamapsychiatry.2021.1961

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。